Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results

RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology

Related Keywords

Canada ,Toronto ,Ontario ,Richmond Hill ,Ukraine ,Canadian ,Frank Michalargias ,Slawomir Majewski ,Toronto Stock Exchange ,Company Statements Of Financial Position ,Drug Administration ,Helix Biopharma Corp ,Company Interim Condensed Financial ,Board Of Directors The Company ,Incentive Program ,Helix Biopharma ,Interim Chief Executive Officer ,Chief Executive ,Cello Healthcare ,Consulting Management ,Financial Position ,Net Loss ,Comprehensive Loss ,Interim Condensed Financial Statements ,Chief Financial ,Looking Statements ,Annual Information Form ,Helix ,Iopharma ,Orp ,Nnounces ,Iscal ,022 ,Second ,Quarter ,Results ,